-transparent.png){kind=logo}
Tamoxifen (20 mg twice daily) was given to ten patients with breast cancer whose immune functions were determined prior to and 3, 6, and 12 months after starting tamoxifen therapy. No consistent changes could be observed in erythrocyte rosette-forming cell counts, erythrocyte antibody rosette-forming cells, active erythrocyte rosette-forming cells, theophylline-resistant rosette-forming cells, surface immunoglobulin-positive cells, and responses to mitogens phytohemagglutinin and concanavalin A. Erythrocyte antibody rosette-forming cells decreased significantly, however, at 6 months and active erythrocyte rosette-forming cells at 12 months after starting tamoxifen. We conclude that no change in the immune capacity could be detected during tamoxifen treatment.
H Joensuu, and
A Toivanen, and
E Nordman
December 1990,
Methods and findings in experimental and clinical pharmacology,
H Joensuu, and
A Toivanen, and
E Nordman
May 1992,
Acta virologica,
H Joensuu, and
A Toivanen, and
E Nordman
April 1989,
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
H Joensuu, and
A Toivanen, and
E Nordman
April 2000,
Sheng li ke xue jin zhan [Progress in physiology],
H Joensuu, and
A Toivanen, and
E Nordman
November 1992,
Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS,
H Joensuu, and
A Toivanen, and
E Nordman
May 1993,
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
H Joensuu, and
A Toivanen, and
E Nordman
September 2020,
Scientific reports,
H Joensuu, and
A Toivanen, and
E Nordman
August 2003,
Clinical chemistry and laboratory medicine,
H Joensuu, and
A Toivanen, and
E Nordman
May 1993,
BMJ (Clinical research ed.),
H Joensuu, and
A Toivanen, and
E Nordman
May 2007,
Cell biology and toxicology,
